Immunotherapy Archives

News and Trends 12 Jul 2018

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […]

July 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

News and Trends 8 Jun 2018

People with Innate Resistance to HIV Could Provide a Functional HIV Cure

In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […]

June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

DBV Technologies Immunotherapy Milk Allergy

News and Trends 29 May 2018

This Immunotherapy Could Be The First to Treat Milk Allergy in Children

DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs in France, is developing a skin patch technology to treat several forms of food allergies. The company has released new, promising data on its milk […]

May 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 May 2018

Positive House Dust Mite Immunotherapy Results for UK Biotech

British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage […]

May 29, 2018 - 1 minutemin - By Helen Albert

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2018

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […]

May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Apr 2018

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […]

April 23, 2018 - 3 minutesmins - By Editorial Team

News and Trends 11 Apr 2018

French CAR-T Developer Raises $164M Despite a Challenging Road

Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […]

April 11, 2018 - 3 minutesmins - By Alexander Burik

OSE Immunotherapeutics Boehringer Ingelheim

News and Trends 5 Apr 2018

Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech

OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has set its eyes on a new type of checkpoint inhibitor being developed by the French biotech. OSE Immunotherapeutics has entered a global license and collaboration deal with Boehringer Ingelheim for the development of OSE-172, a checkpoint inhibitor antibody to treat […]

April 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Mar 2018

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

IO Biotech will test its immune modulator in combination with Merck’s checkpoint inhibitor Keytruda, known for curing former US President Jimmy Carter’s cancer. IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint […]

March 13, 2018 - 2 minutesmins - By Alexander Burik

In Depth 13 Mar 2018

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […]

March 13, 2018 - 6 minutesmins - By Editorial Team

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Update: Yet Another ADC Company Makes Bank, This Time in Series B

People with Innate Resistance to HIV Could Provide a Functional HIV Cure

This Immunotherapy Could Be The First to Treat Milk Allergy in Children

Positive House Dust Mite Immunotherapy Results for UK Biotech

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

French CAR-T Developer Raises $164M Despite a Challenging Road

Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!